AGP Picks
View all

New Hampshire Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.

Press releases published on July 1, 2026

Rentschler Biopharma appoints Dr. Torsten Woehr as Chief Executive Officer
How Meaningful Work Supports Long-Term Sobriety
Managing Mental Health During the Summer
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Correction: Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares
Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Medline to report second quarter 2026 results on August 5, 2026
LiveWorld Names Rob Thomas Vice President, Creative Director to Support Growing Healthcare Creative Practice
JenaValve Recaps Key Highlights Including Late-Breaking Clinical Data from New York Valves 2026
Creative Medical Technology Holdings Issues Mid-Year Update
Rethink Food and Just Salad Roll Out Rethink Food Bowl for July
Amoéba has received marketing authorization in France for its biofungicide AXPERA
Amoéba obtient l’autorisation de mise sur le marché en France pour son biofongicide AXPERA
Amoéba verkrijgt in Frankrijk een vergunning voor het in de handel brengen van zijn biofungicide AXPERA
Amoéba obtém autorização de colocação no mercado em França para o seu biofungicida AXPERA
Amoéba obtiene la autorización de comercialización en Francia para su biofungicida AXPERA
Amoéba ottiene l’autorizzazione all'immissione in commercio in Francia per il suo biofungicida AXPERA

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

New Hampshire Health Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.